CM 4620

Catalog No.S6834

For research use only.

CM 4620 is an inhibitor of calcium-release activated calcium-channel (CRAC channel). CM4620 inhibits Orai1/STIM1-mediated Ca2+ currents and Orai2/STIM1-mediated currents with IC50 of near 120 nM and 900 nM, respectively.

CM 4620 Chemical Structure

CAS No. 1713240-67-5

Purity & Quality Control

Choose Selective Calcium Channel Inhibitors

Other Calcium Channel Products

Biological Activity

Description CM 4620 is an inhibitor of calcium-release activated calcium-channel (CRAC channel). CM4620 inhibits Orai1/STIM1-mediated Ca2+ currents and Orai2/STIM1-mediated currents with IC50 of near 120 nM and 900 nM, respectively.
Targets
Orai1/STIM1-mediated Ca2+ currents [1]
(Cell-free assay)
Orai2/STIM1-mediated currents [1]
(Cell-free assay)
120 nM 900 nM

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 421.76
Formula

C19H11ClF3N3O3

CAS No. 1713240-67-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(=CC=C1)F)C(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3Cl)OC(O4)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04661540 Active not recruiting Drug: CM4620-IE (Injectable Emulsion)|Drug: Placebo Pneumonia CalciMedica Inc.|Northwestern University March 2 2021 Phase 2
NCT04195347 Recruiting Drug: CM4620 Acute Pancreatitis St. Jude Children''s Research Hospital|CalciMedica Inc. September 4 2020 Phase 1|Phase 2
NCT04345614 Completed Drug: Auxora|Drug: Placebo Pneumonia CalciMedica Inc. April 8 2020 Phase 2
NCT03709342 Completed Drug: CM4620-IE Acute Pancreatitis CalciMedica Inc. January 6 2019 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy CM 4620 | CM 4620 supplier | purchase CM 4620 | CM 4620 cost | CM 4620 manufacturer | order CM 4620 | CM 4620 distributor